INOTECH starts Morquio Type A clinical program
Basel / Switzerland, December 21, 2005
Sophie (left, 6) & Maria (12)
Dear Morquio Community,
It is a great honour for Inotech Biotechnologies Ltd. to announce that Saint Louis University, Prof. Shunji Tomatsu, and Inotech initiated to collaborate and conduct the Morquio Type A clinical program with Morquio families, Morquio Foundations, and MPS Societies.
Inotech is aware about the commitment and responsibility towards all Morquio children and families and will do its best to bring this program into clinic by the beginning of 2007. Inotech guarantees and confirms to the Morquio Community to take the Morquio project as # 1 priority project.
Two months ago, a close friend of mine asked me for support within the biotech industry to find a commercial partner for the enzyme replacement therapy. His daughter, Sophie (6), has Morquio and he has heard from Prof. Tomatsu having a new cell line producing said enzyme. That’s where we entered into the Morquio Community and since then, I am very touched about Sophie and as a result, highly motivated to set-up as soon as possible this respective enzyme therapy.
Who is Inotech ?
Inotech is a biotech company based in Basle, Switzerland. We focus on the GMP production of biopharmaceuticals derived from mammalian cells. We show a R&D department, clean rooms and respective bioreactor facilities as well as all regulatory know-how and persons.
Inotech has its core competence in the development and GMP production of recombinant biopharmaceuticals as e.g. monoclonal antibodies, hormones, and enzymes. We have a highly motivated team with long-term industrial background.
What are next steps?
Today, we have started the Project with the production of enzymes for a confirmatory pre-clinical study which will be conducted together with Prof. Tomatsu. In parallel, we will file the respective regulatory papers towards the FDA and organize all topics in order to be able to start the first clinical trial in Q1 / 2007 according actual planning. This initial clinical trial will be executed and supervised by Prof. Tomatsu and his team at St. Louis University.
As a prerequisite for these clinical studies we need your help. Data collection of as many as possible of Morquio children is vital. Together with the International Morquio Organization (the Morquio registry program) and MPS Societies, we will inform you precisely about the status of the project on a regular basis.
We are very happy to start this program and wish you Mary Christmas and a Happy New Year.
Yours sincerely,
Dr. Christoph Heinzen
CEO
Inotech Biotechnologies Ltd.
Basel, Switzerland
INOTECH BIOTECHNOLOGIES LTD. – Eulerstrasse 55 – 4003 Basel – Switzerland
Phone ++41 61 227 78 11 / Fax ++41 61 271 83 59 / www.inotech.ch
Share with your friends: | 
